Merck (MRK) and Hansoh Pharma, a Chinese biopharmaceutical company, announced that they have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist. Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535. Hansoh Pharma will receive an upfront payment of $112M and is eligible to receive up to $1.9B in milestone payments associated with the development, regulatory approval and commercialization of the candidate, as well as royalties on sales. Hansoh Pharma may co-promote or solely commercialize HS-10535 in China subject to certain conditions. Merck will record a pre-tax charge of $112M, or 4c per share, to be included in GAAP and non-GAAP results in the Q4.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Barclays fact-checked Trump comments on pharmacy benefit managers
- Merck’s Biologics License Application for clesrovimab accepted by FDA
- Merck to discontinue Phase 3 KeyVibe-003, KeyVibe-007 trials
- Merck announces approval of KEYTRUDA in China in combination with chemotherapy
- A Dissapointing Week for Dow Jones Industrial Average Puts It in the Red